Litcius/Paper detail

Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma

Blair McNamara, Michelle Greenman, Stefania Bellone, Luca A Santin, Cem Demirkiran, Levent Mutlu, Tobias M.P. Hartwich, Yang Yang‐Hartwich, Elena Ratner, Peter E. Schwartz, Alessandro D. Santin

2024Gynecologic Oncology16 citationsDOI

Topics & Concepts

MedicineTrophoblastConjugateAntibodyAntibody-drug conjugateOvarian carcinomaCancer researchAntigenDrugOvarian cancerImmunologyMonoclonal antibodyPharmacologyCancerInternal medicinePregnancyBiologyFetusPlacentaGeneticsMathematical analysisMathematicsHER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchCancer Cells and Metastasis
Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma | Litcius